UIPATH-A (PATH)
$12.36
0.06 (0.49%)
PATH Stock Quote Delayed 30 Minutes
UiPath Stock Will Need Both AI and Ingenuity to Make Profit
PATH stock is suitable for growth, unsuitable for value now. Acquiring profitability is challenging and the company must find a solution to get there.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$12.73
Market Cap
5.95B
PE Ratio
-55.45
EPS
-0.2229
Volume (Avg. Vol.)
7.64M
Day's Range
$12.27 - $13.04
52-Week Range
$10.37 - $25.47
Dividend & Yield
N/A (N/A)
PATH Stock Predictions, Articles, and UIPATH-A News
UiPath Is Set for a 2022 Comeback
Don't throw out the baby with the bathwater. PATH stock is one of 2021's fallen tech plays that still has a good shot at recovering.
UiPath Needs Time to Reverse the Tide in Its Favor
PATH stock had a rough start on Wall Street. But it's at the forefront of the automation trend, so long-term investors will see the rewards.
UiPath Price Predictions: Why One Analyst Sees PATH Stock Hitting $74
Shares of PATH stock traded higher this morning following Morgan Stanley's upgrade. Let's look at some other UiPath price predictions.
Capture a Piece of a $60+ Billion Opportunity With UiPath
Ready for the robot revolution? If so, then PATH stock can offer you a rare, pure play in the AI-augmented work-automation niche.
UiPath Is a Buy After Its Steep Decline
PATH stock was arguably overpriced following its sizzling IPO. Now that the shares have cooled off, however, UiPath is worth a second look.
Alliances With Cloud Leaders Will Set UiPath Stock in Motion
PATH stock has been on the wrong path but should turn around soon as more businesses recognize the importance of enterprise automation.
UiPath Is Losing Money on a Cash Flow Basis Leaving It Lost In Its Way
PATH stock is likely to take another 33% drop to at least $33.59, as its overvalued price-to-sales multiple deflates.
Add a Cathie Wood-Approved Software Startup to Your Portfolio With UiPath
You can give PATH stock a try because Cathie Wood's fund added it or simply because you don't want to resist the automation revolution.
PATH Stock: 13 Things to Know as UiPath Shares Slump Today
UiPath (PATH) stock is falling hard on Wednesday following the release of its earnings report for the second quarter of fiscal 2022.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Welcome back, trader! We're kicking off the day with an overview of the biggest pre-market stock movers for Wednesday to keep an eye on!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! Let's keep the positive momentum going with a look at the biggest pre-market stock movers for Wednesday.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on EV stocks, talk of a Bitcoin crash and the UiPath stock IPO.
PATH Stock: 18 Things for Potential UiPath Investors to Know as Shares Begin Trading
UiPath (PATH) stock is set to start trading today and there's plenty that investors need to know about the company before that happens.
UiPath IPO: When Does UiPath Go Public? What Is the PATH Stock IPO Price Range?
The UiPath IPO is quickly approaching. Here is what you need to know about the PATH stock IPO price range and everything else.
7 Pharmaceutical Stocks to Buy Now
Seven pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
8 Pharmaceutical Stocks to Buy Now
This week, eight pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
8 Pharmaceutical Stocks to Buy Now
Eight pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
